A top generic drug maker will admit that it fixed prices of a popular cholesterol drug and agree to pay more than US$24 million as part of the Justice Department’s broad crackdown on price fixing and bid rigging in the generic drug market, according to The New York Times.
Apotex is expected to settle charges with the Justice Department as early as Thursday, May 7, that it worked with other drug companies to inflate the price of its cholesterol drug, pravastatin, from 2013 to 2015, according to the people familiar with the talks, who spoke on condition of anonymity because they were not authorized to discuss the documents before they were filed.
The Justice Department’s investigation into generic drug prices, which should remain low and stable, is one of several inquiries into significant price increases that have driven up health costs for consumers and government programs like Medicare.
Congress has been investigating the rising costs of several popular generic drugs over the past several years and state attorneys general have subpoenaed drug makers. President Trump and Democratic politicians have regularly called for costs to be constrained.
Full Content: New York Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Competition Commission of India to Probe AI Landscape for Competition
Apr 23, 2024 by
CPI
Canada’s Agricultural Giants in Antitrust Spotlight
Apr 23, 2024 by
CPI
US House Passes Bill That Could Lead to TikTok Ban
Apr 23, 2024 by
CPI
ADM CFO Resigns Amidst DOJ Investigation Into Accounting Issues
Apr 23, 2024 by
CPI
FTC Throws the Bag: Tapestry’s Capri Deal Blocked Over Market Monopoly Concerns
Apr 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI